Outlook Therapeutics (OTLK) Streamlines Operations

Go back to Outlook Therapeutics (OTLK) Streamlines Operations

Outlook Therapeutics® Streamlines Operations

December 13, 2024 4:30 PM UTC

Full NORSE EIGHT Data Readout Expected January 2025

ISELIN, N.J., Dec. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today... More